David A. Siegel Cabaletta Bio, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Cabaletta Bio, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 331,000 shares of CABA stock, worth $764,610. This represents 0.0% of its overall portfolio holdings.
Number of Shares
331,000
Previous 413,600
19.97%
Holding current value
$764,610
Previous $628,000
22.77%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding CABA
# of Institutions
83Shares Held
72.8MCall Options Held
1.1MPut Options Held
14.9K-
Bain Capital Life Sciences Investors, LLC Boston, MA9.68MShares$22.4 Million7.24% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA8.83MShares$20.4 Million0.03% of portfolio
-
Jennison Associates LLC8.5MShares$19.6 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD8.36MShares$19.3 Million0.01% of portfolio
-
Cormorant Asset Management, LP Boston, MA5MShares$11.6 Million1.86% of portfolio
About Cabaletta Bio, Inc.
- Ticker CABA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,014,000
- Market Cap $67M
- Description
- Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce di...